Literature DB >> 32133137

Comparative efficacy and safety of interventions for preventing chemotherapy-induced oral mucositis in adult cancer patients: a systematic review and network meta-analysis.

Preyanate Wilairat1,2, Kirati Kengkla1,2, Thanatchai Kaewpanan1, Jirapat Kaewthong1, Sorave Ruankon1, Chulalak Subthaweesin1, David D Stenehjem3, Surasak Saokaew1,2,4,5,6.   

Abstract

Objective: To examine the comparative efficacy and safety of interventions for preventing chemotherapy-induced oral mucositis (OM) in adult cancer patients.
Methods: We searched PubMed, Embase and the Cochrane Central systematically for the randomised control trials (RCTs) of interventions for preventing OM. Network meta-analysis (NMA) was performed to estimate risk ratios (RR) and 95% confidence intervals (CI) from both direct and indirect evidence. The primary outcome was any grade of OM. Secondary outcomes were mild-moderate OM, severe OM and adverse events, such as taste disturbance and gastrointestinal adverse events. This study was registered with PROSPERO, number CRD42016052489.
Results: A total of 29 RCTs with 2348 patients (median age, 56.1 years; 57.5% male) were included. Cryotherapy was associated with a significantly lower risk of OM than control (RR 0.51, 95% CI 0.38 to 0.68), and zinc sulphate (RR 0.47, 95% CI 0.23 to 0.97), but not significantly lower than sucralfate and palifermin. No significant differences were observed between cryotherapy and control for taste disturbance and gastrointestinal adverse events. Palifermin was associated with the highest risk of taste disturbance. Conclusions: This NMA suggests that cryotherapy was the most effective intervention for preventing chemotherapy-induced OM with a safety profile similar to control, but not significantly lower than sucralfate and palifermin. Large RCTs are needed to confirm these findings. © European Association of Hospital Pharmacists 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  cancer; chemotherapy; mucositis; network meta-analysis; prevention

Year:  2018        PMID: 32133137      PMCID: PMC7043259          DOI: 10.1136/ejhpharm-2018-001649

Source DB:  PubMed          Journal:  Eur J Hosp Pharm        ISSN: 2047-9956


  60 in total

1.  Network meta-analysis for indirect treatment comparisons.

Authors:  Thomas Lumley
Journal:  Stat Med       Date:  2002-08-30       Impact factor: 2.373

2.  GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables.

Authors:  Gordon Guyatt; Andrew D Oxman; Elie A Akl; Regina Kunz; Gunn Vist; Jan Brozek; Susan Norris; Yngve Falck-Ytter; Paul Glasziou; Hans DeBeer; Roman Jaeschke; David Rind; Joerg Meerpohl; Philipp Dahm; Holger J Schünemann
Journal:  J Clin Epidemiol       Date:  2010-12-31       Impact factor: 6.437

3.  Pharmacoeconomic analysis of palifermin to prevent mucositis among patients undergoing autologous hematopoietic stem cell transplantation.

Authors:  Ajay K Nooka; Heather R Johnson; Jonathan L Kaufman; Christopher R Flowers; Amelia Langston; Conor Steuer; Michael Graiser; Zahir Ali; Nishi N Shah; Sravanti Rangaraju; Dana Nickleach; Jingjing Gao; Sagar Lonial; Edmund K Waller
Journal:  Biol Blood Marrow Transplant       Date:  2014-03-06       Impact factor: 5.742

4.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

5.  Mucositis: Its Occurrence, Consequences, and Treatment in the Oncology Setting.

Authors: 
Journal:  Oncologist       Date:  1998

6.  Economic impact of palifermin on the costs of hospitalization for autologous hematopoietic stem-cell transplant: analysis of phase 3 trial results.

Authors:  Linda S Elting; Ya-Chen Tina Shih; Patrick J Stiff; William Bensinger; Scott B Cantor; Catherine Cooksley; Ricardo Spielberger; Christos Emmanoulides
Journal:  Biol Blood Marrow Transplant       Date:  2007-04-23       Impact factor: 5.742

7.  Efficacy of Sucralfate Mouth Wash in Prevention of 5-fluorouracil Induced Oral Mucositis: A Prospective, Randomized, Double-Blind, Controlled Trial.

Authors:  Shahram Ala; Majid Saeedi; Ghasem Janbabai; Reza Ganji; Elham Azhdari; Afshin Shiva
Journal:  Nutr Cancer       Date:  2016-03-23       Impact factor: 2.900

8.  Sucralfate mouthwash for prevention and treatment of 5-fluorouracil-induced mucositis: a randomized, placebo-controlled trial.

Authors:  Michelle Nottage; Sue-Anne McLachlan; Mary-Anne Brittain; Amit Oza; David Hedley; Ronald Feld; Lillian L Siu; Gregory Pond; Malcolm J Moore
Journal:  Support Care Cancer       Date:  2002-07-23       Impact factor: 3.603

9.  Evaluation of inconsistency in networks of interventions.

Authors:  Areti Angeliki Veroniki; Haris S Vasiliadis; Julian P T Higgins; Georgia Salanti
Journal:  Int J Epidemiol       Date:  2013-02       Impact factor: 7.196

10.  A randomized trial of amifostine in patients with high-dose VIC chemotherapy plus autologous blood stem cell transplantation.

Authors:  J T Hartmann; A von Vangerow; L M Fels; S Knop; H Stolte; L Kanz; C Bokemeyer
Journal:  Br J Cancer       Date:  2001-02-02       Impact factor: 7.640

View more
  2 in total

1.  Sucralfate enemas reduce the oxidative tissue damage and preserves the contents of E-cadherin and ?-catenin in colonic mucosa without fecal stream.

Authors:  Daniela Tiemi Sato; Fabio Guilherme Campos; Paulo Gustavo Kotze; Roberta Laís Santos Mendonça; Danilo Toshio Kanno; José Aires Pereira; Carlos Augusto Real Martinez
Journal:  Acta Cir Bras       Date:  2021-11-29       Impact factor: 1.388

Review 2.  Safety, Precautions, and Modalities in Cancer Rehabilitation: an Updated Review.

Authors:  Jasmine Y Zheng; Alyssa C Mixon; Mitra D McLarney
Journal:  Curr Phys Med Rehabil Rep       Date:  2021-06-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.